

## ELIAS Animal Health Continues Development of Canine Cancer Immunotherapy Technology

---

ELIAS Animal Health is continuing its work in developing a new cancer immunotherapy – ELIAS cancer immunotherapy (ECI®) – for the treatment of cancer in dogs. In the spring of 2020, the company launched a randomized pivotal study to compare ECI and carboplatin for the treatment of canine osteosarcoma.

The aim of the clinical trial is to evaluate the efficacy and safety of ECI compared to the current standard of care carboplatin chemotherapy. ECI is a form of immunotherapy that involves treating the patient with its own cancer-specific “killer” T cells. Following surgery, patients are randomized into two cohorts which receive either the experimental immunotherapy or chemotherapy. ELIAS will evaluate data from this clinical trial in its pursuit of USDA licensure.

Ten investigation sites across the U.S. are participating in the study; as of late February, 85 patients have either completed the therapeutic protocol or are currently undergoing therapy. The trial is projected to reach full enrollment in early 2021, with a final data readout expected in 2022.

In addition, 25 veterinary hospitals are offering ECI as an experimental product under 9 CFR 103.3 to treat canine osteosarcoma patients.

The company is also developing protocols for treatment of other cancers.

Learn more about ECI at [eliasanimalhealth.com](http://eliasanimalhealth.com).